Investment Thesis
Dogwood Therapeutics is a development-stage biotech with negligible revenue ($22.8K) and significant operating losses (-$5.1M), indicating failed or severely delayed commercialization. Despite a solid balance sheet with $13.2M cash and no debt, the company is burning cash at -$4.6M annually with approximately 2.8 years of runway at current burn rates, presenting substantial execution risk without evidence of successful market traction.
Strengths
- Strong balance sheet with $80.6M equity and minimal liabilities ($14.6M)
- No long-term debt burden; capital structure unlevered
- Excellent liquidity position with 5.86x current ratio providing operational runway
- Recent insider activity (4 Form 4 filings) suggests active management engagement
Risks
- Pre-revenue stage with only $22.8K in revenue despite -$5.1M operating losses
- Severely negative operating cash flow of -$4.6M indicates unsustainable cash burn
- Minimal commercial product traction despite being at development/commercialization stage
- Approximately 2.8-year cash runway at current burn rate; requires successful capital raise or revenue inflection
- Typical biotech execution risks: clinical trial failures, regulatory rejection, market adoption challenges
Key Metrics to Watch
- Revenue growth trajectory and product commercialization milestones
- Operating cash burn rate and remaining cash runway
- Clinical trial progress, regulatory approvals, and pipeline advancement
Financial Metrics
Revenue
22.8K
Net Income
-5.0M
EPS (Diluted)
$-0.15
Free Cash Flow
-4.6M
Total Assets
95.2M
Cash
13.2M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-22,298.0%
Net Margin
-21,903.8%
ROE
-6.2%
ROA
-5.2%
FCF Margin
-20,149.3%
Balance Sheet & Liquidity
Current Ratio
5.86x
Quick Ratio
5.86x
Debt/Equity
0.00x
Debt/Assets
15.3%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-16T09:03:07.587164 |
Data as of: 2026-03-31 |
Powered by Claude AI